tiprankstipranks
Advertisement
Advertisement

NAMS Stock Latest News

NewAmsterdam Pharma: Advancing EU Launch and CV Outcomes Pathway Underpins Unchanged $48 Price Target and Buy Rating
RatingsNewAmsterdam Pharma: Advancing EU Launch and CV Outcomes Pathway Underpins Unchanged $48 Price Target and Buy Rating
3d ago
NAMS
NewAmsterdam announces positive CHMP opinion for Ubeslo and Evlarco
PremiumThe Fly
NewAmsterdam announces positive CHMP opinion for Ubeslo and Evlarco
3d ago
NAMS
NewAmsterdam Pharma Wins EMA Backing for Obicetrapib Therapies
PremiumCompany Announcements
NewAmsterdam Pharma Wins EMA Backing for Obicetrapib Therapies
3d ago
8K
NAMS
NewAmsterdam Pharma Announces COO Transition and Advisory Role
PremiumCompany Announcements
NewAmsterdam Pharma Announces COO Transition and Advisory Role
5d ago
8K
NAMS
NewAmsterdam Pharma initiated with an Outperform at BMO Capital
PremiumThe Fly
NewAmsterdam Pharma initiated with an Outperform at BMO Capital
7d ago
NAMS
Pantginis Boosts Price Target on NewAmsterdam as Obicetrapib’s Broad Lipid Profile and CV Outcomes Potential Drive Buy Rating
PremiumRatingsPantginis Boosts Price Target on NewAmsterdam as Obicetrapib’s Broad Lipid Profile and CV Outcomes Potential Drive Buy Rating
11d ago
NAMS
NewAmsterdam Pharma price target raised to $51 from $47 at RBC Capital
Premium
The Fly
NewAmsterdam Pharma price target raised to $51 from $47 at RBC Capital
27d ago
NAMS
NewAmsterdam Shareholders Approve ESPP and Governance Proposals
Premium
Company Announcements
NewAmsterdam Shareholders Approve ESPP and Governance Proposals
2M ago
8K
NAMS
NewAmsterdam Pharma reports Q1 revenue $3.04M, consensus $925,520
PremiumThe Fly
NewAmsterdam Pharma reports Q1 revenue $3.04M, consensus $925,520
3M ago
NAMS
NewAmsterdam Pharma management to meet with Piper Sandler
PremiumThe Fly
NewAmsterdam Pharma management to meet with Piper Sandler
3M ago
NAMS
NewAmsterdam Pharma Announces Chief Accounting Officer Transition Agreement
PremiumCompany Announcements
NewAmsterdam Pharma Announces Chief Accounting Officer Transition Agreement
3M ago
8K
NAMS
NewAmsterdam Pharma: Undervalued Growth Story With Upcoming Clinical Catalysts Supporting Buy Rating
PremiumRatings
NewAmsterdam Pharma: Undervalued Growth Story With Upcoming Clinical Catalysts Supporting Buy Rating
3M ago
NAMS
NewAmsterdam Pharma initiated with a Buy at Truist
PremiumThe FlyNewAmsterdam Pharma initiated with a Buy at Truist
4M ago
NAMS
NewAmsterdam Highlights Obicetrapib Progress in Investor Presentation
Premium
Company Announcements
NewAmsterdam Highlights Obicetrapib Progress in Investor Presentation
5M ago
8K
NAMS
Reaffirming Buy on NewAmsterdam Pharma: Optimized Expense Outlook and Milestone Upside Strengthen Risk‑Reward Profile
Premium
Ratings
Reaffirming Buy on NewAmsterdam Pharma: Optimized Expense Outlook and Milestone Upside Strengthen Risk‑Reward Profile
5M ago
NAMS
NewAmsterdam Pharma management to meet virtually with Piper Sandler
PremiumThe Fly
NewAmsterdam Pharma management to meet virtually with Piper Sandler
5M ago
NAMS
NewAmsterdam Pharma price target raised to $45 from $41 at Guggenheim
PremiumThe Fly
NewAmsterdam Pharma price target raised to $45 from $41 at Guggenheim
5M ago
NAMS
NewAmsterdam Pharma (NAMS): Buy Rating on Strong PREVAIL Momentum, Broad Phase 3 Cardiovascular Program, and Solid Cash Runway
PremiumRatings
NewAmsterdam Pharma (NAMS): Buy Rating on Strong PREVAIL Momentum, Broad Phase 3 Cardiovascular Program, and Solid Cash Runway
5M ago
NAMS
NewAmsterdam Pharma reports FY25 revenue $22.5M, consensus $23.27M
PremiumThe Fly
NewAmsterdam Pharma reports FY25 revenue $22.5M, consensus $23.27M
5M ago
NAMS
NewAmsterdam Pharma announces upcoming milestones
PremiumThe FlyNewAmsterdam Pharma announces upcoming milestones
5M ago
NAMS
NewAmsterdam Pharma management to meet with Piper Sandler
Premium
The Fly
NewAmsterdam Pharma management to meet with Piper Sandler
6M ago
NAMS
NewAmsterdam Pharma price target raised to $47 from $44 at RBC Capital
Premium
The Fly
NewAmsterdam Pharma price target raised to $47 from $44 at RBC Capital
6M ago
NAMS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >